November 14, 2012—A private, for-profit immunization clinic in Las Vegas has filed a federal lawsuit seeking to stop GlaxoSmithKline (GSK) from selling vaccines to a Nevada local public health entity at voluntarily discounted prices negotiated by the 340B Prime Vendor Program (PVP).
In an Oct. 25 complaint filed in federal district court in Las Vegas, The Vaccine Center argues that the voluntary price reductions on GSK vaccines that Southern Nevada Health District obtains through its participation in PVP represents unlawful price discrimination, monopolization, and restraint of trade under federal and state antitrust laws.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)